Replies to post #331416 on Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

"No idea what you just said"

Which bit of my post did you find unclear?

I'm happy to expand or explain if it helps.

""I am sure you are right about placebo being soc. No way would it be a “sugar pill”"

And I'm pretty sure you're wrong.

There's sufficient uncertainty about the efficacy of remdesivir monotherapy in Covid-19 that to use it as standard of care would border on being unethical.

See here, for example:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext

"In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies."

I'm thinking a sensible design for the three arm study (and I appreciate this may not happen) would be placebo vs remesdivir vs remdesivir plus brilacidin.

In an ideal world I would add a brilacidin alone fourth arm, but sadly this is not an ideal world."

[steelyeye]

And if the interim results of the coming Ph 2 Brilacidin trial are as stellar as the lab findings, there is always the option of halting the trial and giving the placebo patients the REAL drug.

there are more soc options then remdesivir